Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia
نویسندگان
چکیده
Targeted therapy has been the forefront of cancer treatment. Cancer immunotherapy is the most recent focus. In addition, novel immunotherapeutics targeting B cell receptor signaling (e.g., ibrutinib), T cell receptor ( e.g., CART19), and NK cells (e.g., AFM13) are being developed. This review summarized the new development in blinatumomab (MT103/MEDI-538), a first-in-class bispecific T engager (BiTE) antibody against CD19/CD3 in patients with relapsed/refractory precursor B cell acute lymphoid leukemia.
منابع مشابه
A Comparative Investigation of the Bispecific Antibody: Expression in Expi293F Cells and E.Coli
Aims: Bispecific antibodies are capable of targeting two cell surface markers simultaneously. Blinatumomab an anti-CD3/CD19 Bispecific T cell engager antibody (BiTE) is approved for clinical application by FDA. This BiTE effectively targets malignant cells in ALL (Acute Lymphoblastic Leukemia) patients. For production of large quantities of such antibodies in industrial settings choice of host ...
متن کاملBlinatumomab: A Promising New Drug in the Therapeutic Armamentarium for Acute Lymphoblastic Leukemia
The anti CD19/CD3-bispecific T cell–engager monoclonal antibody blinatumomab is an effective drug with an acceptable toxic profile for the treatment of patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. This high efficacy has also been observed in patients with minimal residual disease. These favorable results have led to the investigation of the activity of thi...
متن کاملBlinatumomab-associated vasculitis
ALL: acute lymphoblastic leukemia INTRODUCTION Blinatumomab is the first-in-class bispecific T-cell engager antibody approved for the treatment of refractory acute lymphoblastic leukemia (ALL). It simultaneously binds endogenous CD3 cytotoxic T cells and CD19 B cells, resulting in T-celle mediated serial lysis of normal and malignant B cells. Although studies have been conducted into the incide...
متن کاملIncrease of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab
The bispecific T cell engager blinatumomab has shown encouraging clinical activity in B-precursor acute lymphoblastic leukemia (ALL). However, about half of relapsed/refractory patients do not respond to therapy. Here, we present the case of a 32-year-old male patient with refractory B-precursor ALL who was resistant to treatment with blinatumomab. Bone marrow immunohistochemistry revealed T ce...
متن کاملT-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts
T-cell immunotherapies are promising options in relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL). We investigated the effect of co-signaling molecules on T-cell attack against leukemia mediated by CD19/CD3-bispecific T-cell engager. Primary CD19+ ALL blasts (n≥10) and physiologic CD19+CD10+ bone marrow precursors were screened for 20 co-signaling molecules. PD-L1, PD-1, LAG-3,...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 8 شماره
صفحات -
تاریخ انتشار 2015